NCT00155376

Brief Summary

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Sep 2005

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

September 8, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 12, 2005

Completed
Last Updated

November 28, 2005

Status Verified

April 1, 2005

First QC Date

September 8, 2005

Last Update Submit

November 25, 2005

Conditions

Liver Disease

Outcome Measures

Primary Outcomes (1)

  • MRCP visibility

Interventions

morphine and glucagonDRUG

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • normal volunteer
  • living liver donor

You may not qualify if:

  • COPD
  • chronic liver disease
  • hypersensitive to glucagon
  • insulinoma
  • glucagonoma
  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Province of Taiwan, 100, Taiwan

RECRUITING

MeSH Terms

Conditions

Liver Diseases

Interventions

MorphineGlucagon

Condition Hierarchy (Ancestors)

Digestive System Diseases

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsProglucagonPancreatic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Hon-Man Liu, MD

    National Taiwan University Hospital

    STUDY CHAIR

Central Study Contacts

Yuan-Heng Mo, MD

CONTACT

jamesmyh@ha.mc.ntu.edu.tw

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 8, 2005

First Posted

September 12, 2005

Study Start

September 1, 2005

Study Completion

September 1, 2005

Last Updated

November 28, 2005

Record last verified: 2005-04

Locations

TW(1)